Russell K Pachynski, MD
Academic Appointments
- Instructor, Medicine - Oncology
Key Documents
Contact Information
-
Clinical Offices
Medical Oncology 875 Blake Wilbur Dr. Clinic E MC 5820 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 725-9113
- Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Urologic Oncology
- Genitourinary Cancer
- Oncology
- Immunotherapy
- Prostate Cancer
Honors and Awards
- Pilot Award, Stanford Translational Medicine Program (TRAM) (2012)
- Fellowship Award, California Breast Cancer Research Program (2009-2010)
- ASCO Young Investigator Award, American Society of Clinical Oncology (2009)
- ASCO/AACR Workshop: Methods in Clinical Cancer Research, American Society of Clinical Oncology (2009)
- NCCN Fellows Recognition Program, National Comprehensive Cancer Network (2007)
- American Medical Association Seed Grant Award, American Medical Association (2002)
Scientific Focus
Current Research Interests
Infiltration of specialized immune cells regulates the growth and survival of neoplasia. In a survey of leukocyte chemoattractant expression in public whole genome expression datasets, we found that the gene for chemerin is downregulated during tumorigenesis in animal models and in many human cancers. Low or absent chemerin expression predicted inferior outcomes in melanoma, and tumor-expressed chemerin inhibited in vivo growth of mouse melanoma and breast adenocarcinoma models. Growth inhibition was associated with an altered host response, and was abrogated by NK cell depletion. Intratumoral injection of chemerin also inhibited tumors, suggesting the potential for therapeutic application. We conclude that chemerin is an endogenous tumor suppressive chemoattractant cytokine whose downregulation in neoplasia contributes to immune evasion and tumor growth.
Clinical Trials
- Recruiting Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
- Recruiting DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
- Not Recruiting Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors
- Not Recruiting Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- Not Recruiting BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
Publications
- The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. J Exp Med. 2012; (8): 1427-35
- Plasmacytoid dendritic cells transport peripheral antigens to the thymus to promote central tolerance. Immunity. 2012; (3): 438-50
- CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011; (8): 2423-32
- Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 2011; (18): 4890-901
- Prostate specific antigen doubling time (PSADT) in patients with hormone refractory prostate cancer (HRPC) undergoing docetaxel chemotherapy as a predictor of overall survival. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings. 2007; (18s): 15556
- Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther. 2002; (16): 1971-80
Help